- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.07. | Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update | 266 | GlobeNewswire (Europe) | Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy, is pleased to share this update on the meaningful advancements... ► Artikel lesen | |
| 06.07. | Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel Precision Radionuclide Therapy | 420 | GlobeNewswire (Europe) | Kennewick, WA, July 06, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) for the treatment of cancerous tumors, is pleased... ► Artikel lesen | |
| 11.06. | Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet Manufacturing | 209 | GlobeNewswire (Europe) | Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) for the treatment of cancerous tumors, is pleased... ► Artikel lesen | |
| 05.06. | Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel Precision Radionuclide Therapy | 1 | GlobeNewswire (USA) | ||
| 14.05. | VIVOS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.02. | Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites | 352 | GlobeNewswire (Europe) | Kennewick, WA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel Radionuclide Therapy (PRnT) is preparing to open two new production... ► Artikel lesen | |
| 10.02. | Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel Precision Radionuclide Therapy | 327 | GlobeNewswire (Europe) | Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) with its innovative RadioGel technology, today... ► Artikel lesen | |
| VIVOS Aktie jetzt für 0€ handeln | |||||
| 06.11.25 | Vivos Inc. Issues Shareholder Update Letter | 258 | GlobeNewswire (Europe) | Kennewick, WA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) - The Company continues to prioritize securing FDA Investigational Device Exemption (IDE) approval to initiate human clinical... ► Artikel lesen | |
| 29.10.25 | Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics | 252 | GlobeNewswire (Europe) | Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology... ► Artikel lesen | |
| 29.09.25 | Vivos Inc.: Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India | 246 | GlobeNewswire (Europe) | Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name... ► Artikel lesen | |
| 08.09.25 | Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy | 188 | GlobeNewswire (Europe) | Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for... ► Artikel lesen | |
| 14.08.25 | Vivos Inc.: Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA | 240 | GlobeNewswire (Europe) | Kennewick, WA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Following the 30-day review period, the FDA declined approval of the Radiogel® IDE submission. We are now focused on addressing... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| M1 AESTHETICS | 12,700 | -1,55 % | Dividendenbekanntmachungen (08.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2 MILK COMPANY LIMITED NZATME0002S8 0,4135 NZD 0,2059 EUR AGRANA BETEILIGUNGS-AG AT000AGRANA3 - 0,35 EUR BANK OF CHONGQING CO LTD CNE100001QN2 0... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 62,43 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| FRESENIUS | 47,060 | +0,81 % | EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius hebt aufgrund der starken operativen Geschäftsentwicklung die Ergebnisprognose für das Geschäftsjahr 2026 an | EQS-Ad-hoc: Fresenius SE & Co. KGaA / Schlagwort(e): Prognose / Gesamtjahr
Fresenius SE & Co. KGaA: Fresenius hebt aufgrund der starken operativen Geschäftsentwicklung die Ergebnisprognose... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 39,510 | +1,05 % | Börse am Morgen: Hensoldt, Puma, Siemens Healthineers, Börsentermine - Nord/LB | Die Zahl der Arbeitslosen in Deutschland ist im Juli m/m spürbar um 71.000 auf 3,007 Mio. gestiegen, die Arbeitslosenquote kletterte um um 0,2 PP auf 6,4%. Neben saisonalen Effekten wie dem Ausbildungsende... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 42,050 | +0,41 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| PROGYNY | 28,140 | +0,14 % | Progyny, Inc. Announces Second Quarter 2026 Results | Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDARobust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building SolutionsValue Returned to Shareholders... ► Artikel lesen | |
| BILLIONTOONE | 93,34 | -0,05 % | BillionToOne sinks as outlook unchanged despite surging revenue | ||
| CARL ZEISS MEDITEC | 29,900 | +2,05 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: Rheinmetall, Deutsche Telekom, Siemens, Airbnb & Lyft | © Foto: Julian Stratenschulte/dpa Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| GENEDX | 77,15 | +0,09 % | Cathie Wood's ARK sells Palantir stock, buys GeneDx Holdings | ||
| ALIGNMENT HEALTHCARE | 14,370 | 0,00 % | Can ALHC's Raised 2026 Outlook Offset Heavier Second-Half Spending? | ||
| BETA BIONICS | 15,900 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance | IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 22,450 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results | 2Q'26 Net Income of $9.0M, +236.7% from 2Q'252Q'26 Adjusted EBITDA of $37.4M, +29.1% from 2Q'25Full-Year 2026 Guidance Raised for All Key Financial Metrics ARLINGTON, Va., Aug. 06, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 10,805 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| STARLING ONCOLOGY INSTITUTE | 6,400 | -0,16 % | The Oncology Institute Rebrands as Starling Oncology | CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or "the Company"), one of the largest value-based oncology groups in the United States, announced today that... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 20,390 | -0,10 % | Jefferies senkt Kursziel für Procept BioRobotics nach verfehlten Eingriffszahlen |
Das Unternehmen VIVOS INC kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVOS INC finden Sie auf Wallstreet Online.